Navigation Links
Shell Transfers Its Codexis Shares to Raizen
Date:6/2/2011

REDWOOD CITY, Calif., June 2, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Equilon Enterprises LLC, a wholly owned subsidiary of Royal Dutch Shell plc, has completed the transfer of approximately 5.6 million shares of Codexis common stock (which represents approximately 15.7% of Codexis' total outstanding shares) to Raizen Energia Participacoes S.A., a Brazil-based biofuels joint venture between Shell and Cosan Limited.  This transfer occurred as part of the closing of the joint venture.  As a result of the share transfer, Raizen is now Codexis' largest stockholder, and, under an existing stockholder agreement, has the right to appoint a representative to Codexis' Board of Directors.

"We look forward to the opportunity to work with Raizen in development of biofuels," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.  "With access to feedstocks and experience in ethanol production, Raizen has the potential to accelerate future commercialization of renewable fuels."

About Raizen

Raizen is a $12 billion joint venture with annual production capacity of over 2 billion liters of ethanol, making it the third-largest fuels company in Brazil. It has a retail network of 4,500 fuel stations, 24 sugar mills and an installed capacity of 900MW of electric energy from sugar cane bagasse.

About Codexis

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and in carbon capture. Other potential markets include chemicals and water treatment. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the company's opportunities to develop biofuels with Raizen and Raizen's potential to accelerate future commercialization of renewable fuels. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Factors that could materially affect actual results include the timing, cost and feasibility of the production and commercialization of biofuels derived from cellulose.  Other factors can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:

Media:  Lyn Christenson, lyn.christenson@codexis.com, 650.421.8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212.827.3771
Investors:  Henk Adriaenssens, ir@codexis.com, 650.421.8331


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ben-Gurion U. research leads to improved calcium supplement derived from crustacean shells
2. UCSB physicists challenge classical world with quantum-mechanical implementation of shell game
3. First high-resolution images of bone, tooth and shell formation
4. Spherix Transfers Stock Listing to Nasdaq Capital Market
5. Codexis Reports First Quarter 2011 Results
6. Former Senator Byron Dorgan Elected to Codexis Board
7. Codexis Reports Fourth Quarter and Full Year 2010 Results
8. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
9. Codexis Names Vonnie Estes to New Technology Strategic Planning VP Role
10. Codexis R&D Productivity Panels Also Used By Roche
11. Codexis Names Lori Giver VP Systems Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , February 12, 2016 ... Efforts by Enabling Scientific Understanding of Complex Diseases ... Rare Diseases --> ... diagnostics in South Asia and a leading provider of ... contribute $10 million to the GenomeAsia 100K consortium ...
(Date:2/11/2016)... Germany and GERMANTOWN, ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... RNA Panels for gene expression profiling, expanding QIAGEN,s portfolio ... The panels enable researchers to select from over 20,000 ... and discover interactions between genes, cellular phenotypes and disease ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics, ... sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in the ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... than 150 years, continues today to pursue the highest level of accuracy and ... instruments: the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and tough ...
Breaking Biology Technology:
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/27/2016)... 2016  Rite Track, Inc. a leading semiconductor equipment ... Chester, Ohio announced today the acquisition of PLUS ... in Austin, Texas , will significantly ... modifications, installations and technical support offerings for TEL Track ... commented, "PLUS has provided world class service including refurbishment, ...
Breaking Biology News(10 mins):